Document Detail


Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial.
MedLine Citation:
PMID:  23378346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES/HYPOTHESIS: To investigate the efficacy of an intratympanic steroid as a first-line therapy in patients affected by moderate idiopathic sudden sensorineural hearing loss (ISSNHL).
STUDY DESIGN: Prospective, randomized, triple-blind, placebo-controlled trial.
METHODS: Fifty patients presenting with moderate idiopathic sudden sensorineural hearing loss involving all frequencies from 250 Hz to 8,000 Hz (a flat audiogram) were enrolled. Patients were randomized into two groups of 25 each. The first group (intratympanic steroid) underwent a daily intratympanic administration of prednisolone for 3 consecutive days. Subjects in the second group (control) received a daily intratympanic injection of a saline solution for 3 consecutive days. Audiometric tests were performed at day 7 after the beginning of therapy (T1), and then 10 and 30 days after T1. The patients in both groups who did not show a complete recovery at T1 were treated with oral prednisone at a tapering dose.
RESULTS: In the intratympanic steroid group, 19 out of 25 patients presented at T1 complete recovery (76%), whereas in the control group the number patients who recovered completely at T1 was five out of 25 (20%). The mean pure-tone average (PTA) recorded at T1 shows a statistically significant improvement in the hearing threshold of the first group compared to the control group (P < .01).
CONCLUSIONS: The mean PTA recorded after the first-line approach (T1) demonstrated a significant therapeutic action of the short-duration intratympanic steroid therapy on moderate ISSNHL, with a flat audiogram shape, compared to the natural course of the disease and the placebo effect at that time point.
Authors:
Roberto Filipo; Giuseppe Attanasio; Francesca Y Russo; Marika Viccaro; Patrizia Mancini; Edoardo Covelli
Related Documents :
3191006 - Indications and role of axillofemoral bypass in high-risk patients.
6639166 - The use of operative prebypass arteriography and doppler ultrasound recordings to selec...
11016376 - Minimally invasive direct coronary artery bypass grafting: intermediate-term results.
24893686 - Infliximab as a bridge to remission maintained by antimetabolite therapy in crohn's dis...
12096376 - Use of ultrasound to place central lines.
553516 - Antilymphocyte globulin and adrenal steroids in the treatment of multiple sclerosis: sh...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2013-02-01
Journal Detail:
Title:  The Laryngoscope     Volume:  123     ISSN:  1531-4995     ISO Abbreviation:  Laryngoscope     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-27     Completed Date:  2013-05-28     Revised Date:  2014-04-08    
Medline Journal Info:
Nlm Unique ID:  8607378     Medline TA:  Laryngoscope     Country:  United States    
Other Details:
Languages:  eng     Pagination:  774-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Audiometry, Pure-Tone
Female
Glucocorticoids / administration & dosage*
Hearing Loss, Sensorineural / drug therapy*
Hearing Loss, Sudden / drug therapy*
Humans
Male
Middle Aged
Prednisolone / administration & dosage*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Glucocorticoids; 9PHQ9Y1OLM/Prednisolone
Comments/Corrections
Comment In:
Laryngorhinootologie. 2014 Mar;93(3):156-7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autoimmune gastritis mediated by CD4+ T cells promotes the development of gastric cancer.
Next Document:  Fever as a predictor of doctor shopping in the paediatric population.